Effects of hormone replacement therapy with drospirenone on cardiovascular system in postmenopausal hypertensive women with abdominal obesity
https://doi.org/10.18705/1607-419X-2015-21-4-372-377
Abstract
Objective. To evaluate effects of hormone replacement therapy with drospirenone on cardiovascular system in postmenopausal hypertensive women.
Design and methods. Sixty-three postmenopausal women with hypertension I–II degree, abdominal obesity and climacteric syndrome were examined. During the first month all patients received telmisartan, then women were randomized into two groups — the first group (n = 30) continued treatment with telmisartan, participants of the second group (n = 33) took hormone replacement therapy: estradiol hemihydrates 2 mg + drospirenone 1 mg (HRT) in addition to antihypertensive therapy. Weight, anthropometric measurements, blood pressure (BP), diastolic function were evaluated.
Results. There were additional BP lowering effect, significant decrease in weight and abdominal obesity parameters in group treated with HRT. Improved diastolic function of the left ventricle was more marked in HRT group, but there were no significant differences between two groups.
Conclusions. HRT with drospirenone has beneficial effects on cardiovascular system in postmenopausal hypertensive women with abdominal obesity.
About the Authors
E. I. Baranova
First Pavlov State Medical University of St. Petersburg
Russian Federation
Russian Federation
MD, PhD, DSc, Professor, Department of Therapy №1 with the Course of Endocrinology, Cardiology and Functional Diagnostics n.a. G.F. Lang,
St. Petersburg
O. O. Bolshakova
V.A. Almazov Federal North-West Medical Research Centre;
First Pavlov State Medical University of St. Petersburg
Russian Federation
Russian Federation
MD, PhD, Head, Research Institute of EvidenceBased Medicine and Clinical Trials;
Professor, Department of Therapy №1 with the Course of Endocrinology, Cardiology and Functional Diagnostics n.a. G.F. Lang,
St. Petersburg
I. E. Zazerskaya
V.A. Almazov Federal North-West Medical Research Centre
Russian Federation
Russian Federation
MD, PhD, DSc, Director, Institute of Perinatology and Pediatric, Head, Research Laboratory of Reproduction and Women Health,
St. Petersburg
T. Kh. Yusipova
First Pavlov State Medical University of St. Petersburg
Russian Federation
Russian Federation
MD, Postgraduate Student, Department of Therapy №1 with the Course of Endocrinology, Cardiology and Functional Diagnostics n.a. G.F. Lang,
6/8 L. Tolstoy street, St. Petersburg, 197022
References
1. Маслова Н. П., Баранова Е. И. Гипертоническая болезнь у женщин. Издательство СПбГМУ, 2000. [Maslova NP, Baranova EI. Arterial hypertension in women. Publishing company SPbGMU, 2000. In Russian].
2. Catena C, Colussi G, Brosolo G, Iogna-Prat L, Sechi LA. Aldosterone and aldosterone antagonistsin cardiac disease: what is known, what is new. Am J Cardiovasc Dis. 2012;2(1):50–7.
3. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, PerezA et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999;341(10):709–17.
4. Zannad F, McMurray JJ, Krum H, van Veldhuisen DJ, Swedberg K, Shi H et al. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med. 2011;364(1):11–21.
5. Edelmann F, Wachter R, Schmidt AG, Kraigher-Krainer E, Colantonio C, Kamke W et al.Effect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction: the Aldo-DHF randomized controlled trial. J Am Med Assoc. 2013;309(8):781–791.
6. Mottram PM, Haluska B, Leano R, Cowley D, Stowasser M, Marwick TH. Effect of aldosterone antagonism on myocardial dysfunction in hypertensive patients with diastolic heart failure. Circulation. 2004;110(5):558–565.
7. Mak GJ, Ledwidge MT, Watson CJ, Phelan DM, DawkinsIR, Murphy NF et al. Natural history of markers of collagen turnover in patients with early diastolic dysfunction and impact of eplerenone. J Am Coll Cardiol. 2009;54(18):1674–82.
8. Watson LE, Jewell C, Song J, Dostal DE. Echocardiographic effects of eplerenone and aldosterone in hypertensive rats. Front Biosci. 2013;5:922–927.
9. Losert W, Casals-Stenzel J, Buse M. Progestogens with antimineralocorticoid activity. Arzneimittelforschung. 1985; 35:459–471.
10. Радзинский В.Е., Еремичев Р.Ю. ЗГТ и экстрагенитальные заболевания. Медицинский совет. 2013;8(1):20–22. [Radzinskiy VE, Eremichev RU. Hormone replacement therapy and extragenital disease. Medical Сounsil. 2013;8(1):20–22. In Russian].
11. Мычка В. Б., Кириллова М. Ю., Кузнецова И. В., Войченко Н.А., Федорович А.А., Балахонова Т.В. и др. Современная комбинированная гормональная терапия у женщин в ранней постменопаузе. Кардиоваскулярная терапия и профилактика. 2012;4:42–51. [Mychka VB, Kirillova MYu, Kuznetsova IV, Voychenko NA, Fedorovich AA, Balakhonova TV et al. Modern combined therapy in early postmenopause women. Kardiovaskulyarnaya Terapiya i Profilaktika = Cardiovascular Therapy and Prevention. 2012;11(4):42–51. In Russian].
12. Caprio M, Antelmi A, Chetrite G, Muscat A, Mammi C, Marzolla V et al. Antiadipogenic effects of the mineralocorticoid receptor antagonist drospirenone: potential implications for the treatment of metabolic syndrome. Endocrinology. 2011;152 (1):113–125.
13. Simoncini T, Fu XD, Caruso A, Garibaldi S, Baldacci C, Giretti MS et al. Drospirenone increases endothelial nitric oxide synthesis via a combined action on progesterone and mineralocorticoid receptors. Hum Reprod. 2007;22(8):2325–2334.
14. Arias-Loza PA, Hu K, Schafer A, Bauersachs J, Quaschning T, Galle J et al. Medroxy-progesterone acetate but not drospirenone ablates the protective function of 17-estradiol in aldosterone salt treated rats. Hypertension. 2006;48(5):994–1001.
Review
For citations:
Baranova E.I., Bolshakova O.O., Zazerskaya I.E., Yusipova T.Kh. Effects of hormone replacement therapy with drospirenone on cardiovascular system in postmenopausal hypertensive women with abdominal obesity. "Arterial’naya Gipertenziya" ("Arterial Hypertension"). 2015;21(4):372-377. (In Russ.) https://doi.org/10.18705/1607-419X-2015-21-4-372-377
Views:
1927
Email this article 